Skip to main content

Advertisement

SpringerLink
Log in

Novel Treatments for NEC: Keeping IBD in Mind

  • Small Intestine (J Sellin, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Necrotizing enterocolitis (NEC) is an inflammatory intestinal disease of premature newborns, thought to result in part from overactivity of the innate immune system. NEC has been well-studied from the perspective of prevention; however, after the disease onset, there are limited treatment options to control its progression. This review discusses four potential therapies that target the overactive immune response in NEC: pentoxifylline, platelet activating factor modulators, glucocorticoids, and vasoactive substances. In addition, given the similar pathogenesis of NEC and inflammatory bowel disease (IBD), we propose that IBD therapies could provide promising leads for novel strategies with which to treat NEC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Berman L, Moss RL. Necrotizing enterocolitis: an update. Semin Fetal Neonatal Med. 2011;16(3):145–50. doi:10.1016/j.siny.2011.02.002. An up-to-date review on the pathophysiology, clinical presentation, and management of NEC. The authors also discuss the various preventive measures proposed and tested in NEC.

    Article  PubMed  Google Scholar 

  2. Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clark RH. Necrotizing enterocolitis among neonates in the United States. J Perinatol. 2003;23(4):278–85. doi:10.1038/sj.jp. 7210892.

    Article  PubMed  Google Scholar 

  3. Horwitz JR, Lally KP, Cheu HW, Vazquez WD, Grosfeld JL, Ziegler MM. Complications after surgical intervention for necrotizing enterocolitis: a multicenter review. J Pediatr Surg. 1995;30(7):994–8. discussion 8–9.

    Article  PubMed  CAS  Google Scholar 

  4. Schulzke SM, Deshpande GC, Patole SK. Neurodevelopmental outcomes of very low-birth-weight infants with necrotizing enterocolitis: a systematic review of observational studies. Arch Pediatr Adolesc Med. 2007;161(6):583–90. doi:10.1001/archpedi.161.6.583.

    Article  PubMed  Google Scholar 

  5. Grave GD, Nelson SA, Walker WA, Moss RL, Dvorak B, Hamilton FA, et al. New therapies and preventive approaches for necrotizing enterocolitis: report of a research planning workshop. Pediatr Res. 2007;62(4):510–4. doi:10.1203/PDR.

    Article  PubMed  Google Scholar 

  6. Lin PW, Nasr TR, Stoll BJ. Necrotizing enterocolitis: recent scientific advances in pathophysiology and prevention. Semin Perinatol. 2008;32(2):70–82. doi:10.1053/j.semperi.2008.01.004.

    Article  PubMed  Google Scholar 

  7. Frost BL, Jilling T, Caplan MS. The importance of pro-inflammatory signaling in neonatal necrotizing enterocolitis. Semin Perinatol. 2008;32(2):100–6. doi:10.1053/j.semperi.2008.01.001.

    Article  PubMed  Google Scholar 

  8. Gordon PV, Swanson JR, Attridge JT, Clark R. Emerging trends in acquired neonatal intestinal disease: is it time to abandon Bell’s criteria? J Perinatol. 2007;27(11):661–71. doi:10.1038/sj.jp.7211782.

    Article  PubMed  CAS  Google Scholar 

  9. O’Connor A, Sawin RS. High morbidity of enterostomy and its closure in premature infants with necrotizing enterocolitis. Arch Surg. 1998;133(8):875–80.

    Article  PubMed  Google Scholar 

  10. Patel JC, Tepas 3rd JJ, Huffman SD, Evans JS. Neonatal necrotizing enterocolitis: the long-term perspective. Am Surg. 1998;64(6):575–9. discussion 9–80.

    PubMed  CAS  Google Scholar 

  11. Stanford A, Upperman JS, Boyle P, Schall L, Ojimba JI, Ford HR. Long-term follow-up of patients with necrotizing enterocolitis. J Pediatr Surg. 2002;37(7):1048–50. discussion −50.

    Article  PubMed  Google Scholar 

  12. Piena-Spoel M, Albers MJ, ten Kate J, Tibboel D. Intestinal permeability in newborns with necrotizing enterocolitis and controls: Does the sugar absorption test provide guidelines for the time to (re-)introduce enteral nutrition? J Pediatr Surg. 2001;36(4):587–92. doi:10.1053/jpsu.2001.22288.

    Article  PubMed  CAS  Google Scholar 

  13. Santulli TV, Schullinger JN, Heird WC, Gongaware RD, Wigger J, Barlow B, et al. Acute necrotizing enterocolitis in infancy: a review of 64 cases. Pediatrics. 1975;55(3):376–87.

    PubMed  CAS  Google Scholar 

  14. Anand RJ, Leaphart CL, Mollen KP, Hackam DJ. The role of the intestinal barrier in the pathogenesis of necrotizing enterocolitis. Shock. 2007;27(2):124–33. doi:10.1097/01.shk.0000239774.02904.65.

    Article  PubMed  CAS  Google Scholar 

  15. Li N, Lassman BJ, Liu Z, Liboni K, Neu J. Effects of protein deprivation on growth and small intestine morphology are not improved by glutamine or glutamate in gastrostomy-fed rat pups. J Pediatr Gastroenterol Nutr. 2004;39(1):28–33.

    Article  PubMed  CAS  Google Scholar 

  16. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001;291(5505):881–4. doi:10.1126/science.291.5505.881 291/5505/881.

    Article  PubMed  CAS  Google Scholar 

  17. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229–41. doi:10.1016/j.cell.2004.07.002 S0092867404006610.

    Article  PubMed  CAS  Google Scholar 

  18. Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol. 2007;19(2):70–83. doi:10.1016/j.smim.2007.04.002.

    Article  PubMed  CAS  Google Scholar 

  19. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474(7351):327–36. doi:10.1038/nature10213.

    Article  PubMed  CAS  Google Scholar 

  20. Nanthakumar NN, Fusunyan RD, Sanderson I, Walker WA. Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis. Proc Natl Acad Sci U S A. 2000;97(11):6043–8.

    Article  PubMed  CAS  Google Scholar 

  21. Claud EC, Lu L, Anton PM, Savidge T, Walker WA, Cherayil BJ. Developmentally regulated IkappaB expression in intestinal epithelium and susceptibility to flagellin-induced inflammation. Proc Natl Acad Sci U S A. 2004;101(19):7404–8. doi:10.1073/pnas.0401710101 0401710101.

    Article  PubMed  CAS  Google Scholar 

  22. Claud EC, Savidge T, Walker WA. Modulation of human intestinal epithelial cell IL-8 secretion by human milk factors. Pediatr Res. 2003;53(3):419–25.

    Article  PubMed  CAS  Google Scholar 

  23. Leaphart CL, Cavallo J, Gribar SC, Cetin S, Li J, Branca MF, et al. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol. 2007;179(7):4808–20.

    PubMed  CAS  Google Scholar 

  24. Jilling T, Simon D, Lu J, Meng FJ, Li D, Schy R, et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol. 2006;177(5):3273–82.

    PubMed  CAS  Google Scholar 

  25. Fusunyan RD, Nanthakumar NN, Baldeon ME, Walker WA. Evidence for an innate immune response in the immature human intestine: toll-like receptors on fetal enterocytes. Pediatr Res. 2001;49(4):589–93.

    Article  PubMed  CAS  Google Scholar 

  26. Lotz M, Gutle D, Walther S, Menard S, Bogdan C, Hornef MW. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J Exp Med. 2006;203(4):973–84. doi:10.1084/jem.20050625.

    Article  PubMed  CAS  Google Scholar 

  27. Melmed G, Thomas LS, Lee N, Tesfay SY, Lukasek K, Michelsen KS, et al. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol. 2003;170(3):1406–15.

    PubMed  CAS  Google Scholar 

  28. De Plaen IG, Liu SX, Tian R, Neequaye I, May MJ, Han XB, et al. Inhibition of nuclear factor-kappaB ameliorates bowel injury and prolongs survival in a neonatal rat model of necrotizing enterocolitis. Pediatr Res. 2007;61(6):716–21. doi:10.1203/pdr.0b013e3180534219.

    Article  PubMed  Google Scholar 

  29. Ren Y, Lin CL, Li Z, Chen XY, Huang X, Lui V, et al. Up-regulation of macrophage migration inhibitory factor in infants with acute neonatal necrotizing enterocolitis. Histopathology. 2005;46(6):659–67. doi:10.1111/j.1365-2559.2005.02159.x.

    Article  PubMed  CAS  Google Scholar 

  30. •• Nanthakumar N, Meng D, Goldstein AM, Zhu W, Lu L, Uauy R, et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PLoS One. 2011;6(3):e17776. doi:10.1371/journal.pone.0017776. This paper demostrates that the fetal intestinal tract has an immature, over-active immune system. The authors study human tissues from fetuses, infants with NEC, and non-diseased older children. Through mRNA, protein, and siRNA techniques, they show that developing intestinal tissues express higher levels of pro-inflammatory, and lower levels of anti-inflammatory, molecules.

    Article  PubMed  CAS  Google Scholar 

  31. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr. 1990;116(6):960–4.

    Article  PubMed  CAS  Google Scholar 

  32. Caplan MS, Hsueh W. Necrotizing enterocolitis: role of platelet activating factor, endotoxin, and tumor necrosis factor. J Pediatr. 1990;117(1 Pt 2):S47–51.

    PubMed  CAS  Google Scholar 

  33. Caplan M, Hsueh W, Kelly A, Donovan M. Serum PAF acetylhydrolase increases during neonatal maturation. Prostaglandins. 1990;39(6):705–14.

    PubMed  CAS  Google Scholar 

  34. Amer MD, Hedlund E, Rochester J, Caplan MS. Platelet-activating factor concentration in the stool of human newborns: effects of enteral feeding and neonatal necrotizing enterocolitis. Biol Neonate. 2004;85(3):159–66. doi:10.1159/000075306 75306.

    Article  PubMed  CAS  Google Scholar 

  35. Crowley P, Chalmers I, Keirse MJ. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol. 1990;97(1):11–25.

    Article  PubMed  CAS  Google Scholar 

  36. Smith LM, Qureshi N, Chao CR. Effects of single and multiple courses of antenatal glucocorticoids in preterm newborns less than 30 weeks’ gestation. J Matern Fetal Med. 2000;9(2):131–5. doi:10.1002/(SICI)1520-6661(200003/04)9:2<131::AID-MFM9>3.0.CO;2-M.

    Article  PubMed  CAS  Google Scholar 

  37. Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147(2):192–6. doi:10.1016/j.jpeds.2005.03.054.

    Article  PubMed  Google Scholar 

  38. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005;115(1):1–4. doi:10.1542/peds.2004-1463.

    PubMed  Google Scholar 

  39. • Harris E, Schulzke SM, Patole SK. Pentoxifylline in preterm neonates: a systematic review. Paediatr Drugs. 2010;12(5):301–11. doi:10.2165/11532600-000000000-00000. A review providing an in-depth discussion of using pentoxifylline in premature infants. The authors highlight pentoxifylline’s mechanism of action, as well as the drug’s benefits and risks.

    Article  PubMed  Google Scholar 

  40. Travadi J, Patole S, Charles A, Dvorak B, Doherty D, Simmer K. Pentoxifylline reduces the incidence and severity of necrotizing enterocolitis in a neonatal rat model. Pediatr Res. 2006;60(2):185–9. doi:10.1203/01.pdr.0000228325.24945.ac.

    Article  PubMed  CAS  Google Scholar 

  41. Hammerman C, Goldschmidt D, Caplan MS, Kaplan M, Schimmel MS, Eidelman AI, et al. Amelioration of ischemia-reperfusion injury in rat intestine by pentoxifylline-mediated inhibition of xanthine oxidase. J Pediatr Gastroenterol Nutr. 1999;29(1):69–74.

    Article  PubMed  CAS  Google Scholar 

  42. Zeni F, Pain P, Vindimian M, Gay JP, Gery P, Bertrand M, et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med. 1996;24(2):207–14.

    Article  PubMed  CAS  Google Scholar 

  43. Bienvenu J, Doche C, Gutowski MC, Lenoble M, Lepape A, Perdrix JP. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol. 1995;25 Suppl 2:S80–4.

    Article  PubMed  CAS  Google Scholar 

  44. • Haque KN, Pammi M. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. 2011;10:CD004205. doi:10.1002/14651858.CD004205.pub2. A review of four randomized control trials testing the use of Pentoxifylline for neonatal sepsis and enterocolitis. The authors conclude that pentoxifylline in conjunction with sepsis may have a positive benefit in the setting of sepsis. However, to evaluate the drug’s role in NEC, more studies are needed.

    PubMed  Google Scholar 

  45. Ali W, Ahmed P, Bhat MA, Mushtaq AB, Mushtaq S. Pentoxifylline in the treatment of sepsis in premature infants. JK Pract. 2006;13:204–7.

    Google Scholar 

  46. Hammerman, C. Pentoxifylline in the Treatment of NEC in Premature Neonates. In: Clinical trial.gov. 2008. http://www.clinicaltrials.gov/ct2/home. Accessed 20 April 2012.

  47. Patole, S. Pentoxifylline as a secondary prophylaxis for necrotising enterocolitis in preterm neonates. In: Australian New Zealand Clinical Trials Registry. 2009. http://www.anzctr.org.au/default.aspx. Accessed 20 April 2012.

  48. •• Lu J, Pierce M, Franklin A, Jilling T, Stafforini DM, Caplan M. Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis. Pediatr Res. 2010;68(3):225–30. doi:10.1203/PDR.0b013e3181eb2efe. A study demonstrating the role of high PAF levels in the pathogenesis of NEC. The authors created mice deficient in PAF-AH, an enzyme that normally degrades PAF. When knock-out mice (vs. controls) were treated to induce an NEC-like condition, they had a higher incidence of NEC and greater expression of pro-inflammtory molecules.

    Article  PubMed  CAS  Google Scholar 

  49. Moya FR, Eguchi H, Zhao B, Furukawa M, Sfeir J, Osorio M, et al. Platelet-activating factor acetylhydrolase in term and preterm human milk: a preliminary report. J Pediatr Gastroenterol Nutr. 1994;19(2):236–9.

    Article  PubMed  CAS  Google Scholar 

  50. Caplan MS, Lickerman M, Adler L, Dietsch GN, Yu A. The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis. Pediatr Res. 1997;42(6):779–83.

    Article  PubMed  CAS  Google Scholar 

  51. Nanthakumar NN, Young C, Ko JS, Meng D, Chen J, Buie T, et al. Glucocorticoid responsiveness in developing human intestine: possible role in prevention of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2005;288(1):G85–92. doi:10.1152/ajpgi.00169.2004.

    Article  PubMed  CAS  Google Scholar 

  52. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;1:CD001146. doi:10.1002/14651858.CD001146.

    PubMed  Google Scholar 

  53. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;1:CD001144. doi:10.1002/14651858.CD001144.

    PubMed  Google Scholar 

  54. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;1:CD001145. doi:10.1002/14651858.CD001145.

    PubMed  Google Scholar 

  55. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001;344(2):95–101. doi:10.1056/NEJM200101113440203.

    Article  PubMed  CAS  Google Scholar 

  56. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, et al. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol. 1999;55(5):902–9.

    PubMed  CAS  Google Scholar 

  57. Ito Y, Doelle SM, Clark JA, Halpern MD, McCuskey RS, Dvorak B. Intestinal microcirculatory dysfunction during the development of experimental necrotizing enterocolitis. Pediatr Res. 2007;61(2):180–4. doi:10.1203/pdr.0b013e31802d77db00006450-200702000-00011.

    Article  PubMed  Google Scholar 

  58. Nowicki PT, Dunaway DJ, Nankervis CA, Giannone PJ, Reber KM, Hammond SB, et al. Endothelin-1 in human intestine resected for necrotizing enterocolitis. J Pediatr. 2005;146(6):805–10. doi:10.1016/j.jpeds.2005.01.046.

    Article  PubMed  CAS  Google Scholar 

  59. Oktar BK, Gulpinar MA, Bozkurt A, Ghandour S, Cetinel S, Moini H, et al. Endothelin receptor blockers reduce I/R-induced intestinal mucosal injury: role of blood flow. Am J Physiol Gastrointest Liver Physiol. 2002;282(4):G647–55.

    PubMed  CAS  Google Scholar 

  60. Nowicki PT. The effects of ischemia-reperfusion on endothelial cell function in postnatal intestine. Pediatr Res. 1996;39(2):267–74.

    Article  PubMed  CAS  Google Scholar 

  61. Nowicki PT, Caniano DA, Hammond S, Giannone PJ, Besner GE, Reber KM, et al. Endothelial nitric oxide synthase in human intestine resected for necrotizing enterocolitis. J Pediatr. 2007;150(1):40–5. doi:10.1016/j.jpeds.2006.09.029.

    Article  PubMed  CAS  Google Scholar 

  62. Fukatsu K, Ueno C, Maeshima Y, Hara E, Nagayoshi H, Omata J, et al. Effects of L-arginine infusion during ischemia on gut blood perfusion, oxygen tension, and circulating myeloid cell activation in a murine gut ischemia/reperfusion model. JPEN J Parenter Enter Nutr. 2004;28(4):224–30. discussion 30–1.

    Article  CAS  Google Scholar 

  63. Spanos CP, Papaconstantinou P, Spanos P, Karamouzis M, Lekkas G, Papaconstantinou C. The effect of L-arginine and aprotinin on intestinal ischemia-reperfusion injury. J Gastrointest Surg. 2007;11(3):247–55. doi:10.1007/s11605-007-0102-6.

    Article  PubMed  Google Scholar 

  64. Di Lorenzo M, Bass J, Krantis A. Use of L-arginine in the treatment of experimental necrotizing enterocolitis. J Pediatr Surg. 1995;30(2):235–40. doi:0022-3468(95)90567-7. discussion 40–1.

    Article  PubMed  Google Scholar 

  65. Amin HJ, Zamora SA, McMillan DD, Fick GH, Butzner JD, Parsons HG, et al. Arginine supplementation prevents necrotizing enterocolitis in the premature infant. J Pediatr. 2002;140(4):425–31. doi:10.1067/mpd.2002.123289.

    Article  PubMed  CAS  Google Scholar 

  66. Shah P, Shah V. Arginine supplementation for prevention of necrotising enterocolitis in preterm infants. Cochrane Database Syst Rev. 2007;3:CD004339. doi:10.1002/14651858.CD004339.pub3.

    PubMed  Google Scholar 

  67. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev. 2007;3:CD005494. doi:10.1002/14651858.CD005494.pub2.

    PubMed  Google Scholar 

  68. Seitz G, Warmann SW, Guglielmetti A, Heitmann H, Ruck P, Kreis ME, et al. Protective effect of tumor necrosis factor alpha antibody on experimental necrotizing enterocolitis in the rat. J Pediatr Surg. 2005;40(9):1440–5. doi:10.1016/j.jpedsurg.2005.05.043.

    Article  PubMed  Google Scholar 

  69. Halpern MD, Clark JA, Saunders TA, Doelle SM, Hosseini DM, Stagner AM, et al. Reduction of experimental necrotizing enterocolitis with anti-TNF-alpha. Am J Physiol Gastrointest Liver Physiol. 2006;290(4):G757–64. doi:10.1152/ajpgi.00408.2005.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Section of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, USA

    Sanjiv Harpavat & Mark Gilger

  2. Section of Neonatology, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, USA

    Mohan Pammi

Authors
  1. Sanjiv Harpavat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohan Pammi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Gilger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanjiv Harpavat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harpavat, S., Pammi, M. & Gilger, M. Novel Treatments for NEC: Keeping IBD in Mind. Curr Gastroenterol Rep 14, 373–379 (2012). https://doi.org/10.1007/s11894-012-0267-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-012-0267-3

Keywords

Search

Navigation